title: Tight glycemic control in critical care--the leading role of insulin sensitivity and patient variability: a review and model-based analysis.
abstract: Tight glycemic control (TGC) has emerged as a major research focus in critical care due to its potential to simultaneously reduce both mortality and costs. However, repeating initial successful TGC trials that reduced mortality and other outcomes has proven difficult with more failures than successes. Hence, there has been growing debate over the necessity of TGC, its goals, the risk of severe hypoglycemia, and target cohorts. This paper provides a review of TGC via new analyses of data from several clinical trials, including SPRINT, Glucontrol and a recent NICU study. It thus provides both a review of the problem and major background factors driving it, as well as a novel model-based analysis designed to examine these dynamics from a new perspective. Using these clinical results and analysis, the goal is to develop new insights that shed greater light on the leading factors that make TGC difficult and inconsistent, as well as the requirements they thus impose on the design and implementation of TGC protocols. A model-based analysis of insulin sensitivity using data from three different critical care units, comprising over 75,000h of clinical data, is used to analyse variability in metabolic dynamics using a clinically validated model-based insulin sensitivity metric (S(I)). Variation in S(I) provides a new interpretation and explanation for the variable results seen (across cohorts and studies) in applying TGC. In particular, significant intra- and inter-patient variability in insulin resistance (1/S(I)) is seen be a major confounder that makes TGC difficult over diverse cohorts, yielding variable results over many published studies and protocols. Further factors that exacerbate this variability in glycemic outcome are found to include measurement frequency and whether a protocol is blind to carbohydrate administration.
authors.affiliation: University of Canterbury, Dept of Mechanical Engineering, Centre for Bio-Engineering, Private Bag 4800, Christchurch, New Zealand. geoff.chase@canterbury.ac.nz
authors.forename: J Geoffrey
authors.initials: JG
authors.lastname: Chase
authors.forename: Aaron J
authors.initials: AJ
authors.lastname: Le Compte
authors.forename: Fatanah
authors.initials: F
authors.lastname: Suhaimi
authors.forename: Geoffrey M
authors.initials: GM
authors.lastname: Shaw
authors.forename: Adrienne
authors.initials: A
authors.lastname: Lynn
authors.forename: Jessica
authors.initials: J
authors.lastname: Lin
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Pretty
authors.forename: Normy
authors.initials: N
authors.lastname: Razak
authors.forename: Jacquelyn D
authors.initials: JD
authors.lastname: Parente
authors.forename: Christopher E
authors.initials: CE
authors.lastname: Hann
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Preiser
authors.forename: Thomas
authors.initials: T
authors.lastname: Desaive
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D002986:Clinical Trials as Topic; D003198:Computer Simulation; D003422:Critical Care; D016638:Critical Illness / Q000401:mortality / Q000628:therapy; D006801:Humans; D006943:Hyperglycemia / Q000628:therapy; D007003:Hypoglycemia / Q000628:therapy; D007231:Infant, Newborn; D007333:Insulin Resistance / Q000502:physiology*; D008954:Models, Biological
chemical_list: D001786:Blood Glucose